Application of 'functional equivalence' to payment for office-administered biopharmaceuticals.

The emergence of competing biotech products has led to much discussion about their interchangeability. Beyond the clinical implications of designating products as therapeutically equivalent, the dollars at stake with biopharmaceuticals promise to make reimbursement issues more and more important. Medicare's approach could influence private payers, which have been slower to address these issues.